ResMed Inc. Announces Record Financial Results for the Quarter Ended Septembe...(-------------- ----...),Health

Date:11/5/2009

-------------- ------- ------- Non Current Liabilities: Deferred income taxes 11,548 11,137 Deferred revenue 14,878 15,238 Income taxes payable 3,395 3,110 Long-term debt 95,093 94,191 -------------- ------ ------ Total non-current liabilities 124,914 123,676 ----------------------------- ------- ------- Total liabilities 417,210 392,776 ----------------- ------- ------- Stockholders' Equity: Common Stock 300 301 Additional paid-in capital 545,186 522,982 Retained earnings 736,893 694,791 Treasury stock (244,342) (208,659) Accumulated other comprehensive income 164,889 105,777 -------------------------------------- ------- ------- Total stockholders' equity 1,202,926 1,115,192 -------------------------- --------- --------- Total liabilities and stockholders' equity $1,620,136 $1,507,968 ---------- ----------

SOURCE ResMed Inc.

'/>"/>

SOURCE ResMed Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. ResMed Acquires Laboratoires Narval
2. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
3. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
4. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
5. OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010
6. Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
7. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
8. GSI Group Inc. Announces NASDAQ Delisting and Reports Progress on Revenue Recognition Review and Preliminary Third Quarter 2009 Bookings and Cash Balance
9. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
10. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
11. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF